Dr. Frederick C. Beddingfield III is the Chief Executive Officer and Board Director of Rubedo Life Sciences, a biopharmaceutical company focused on developing first-in-class therapies targeting senescent cells to treat age-related diseases. He brings over 20 years of experience in life sciences leadership, having previously served as CEO of Sienna Biopharmaceuticals, which he took public in 2017, and as Chief Medical Officer at Kythera Biopharmaceuticals, acquired by Allergan for $2.1 billion. During his decade-long tenure at Allergan, Dr. Beddingfield held senior roles, including Therapeutic Area Head of Dermatology and Chief Medical Officer of Allergan Medical, leading the development and approval of globally recognized brands such as Botox®, Juvederm®, and Kybella® . He also served as an Executive Partner at Apollo Health Ventures, focusing on biotechnology startups in longevity and age-related diseases.